AJP - Heart Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 288: H2819-H2827, 2005. First published January 28, 2005; doi:10.1152/ajpheart.00862.2004
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/6/H2819    most recent
00862.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mizuno, T.
Right arrow Articles by Li, R.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mizuno, T.
Right arrow Articles by Li, R.-K.

Overexpression of elastin fragments in infarcted myocardium attenuates scar expansion and heart dysfunction

Tomohiro Mizuno, Donald A. G. Mickle, Chris G. Kiani, and Ren-Ke Li

Toronto General Research Institute, Division of Cardiovascular Surgery, Department of Surgery, Toronto General Hospital, University of Toronto, Toronto, Canada

Submitted 23 August 2004 ; accepted in final form 27 January 2005


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Ventricular dilation after myocardial infarction can cause heart failure. Increasing strength and elasticity in the infarct region might prevent ventricular dilation. Because elastin provides strength, extensibility, and resilience to tissues and maintains tissue architecture, we studied the effect of elastin expression in the infarct on scar expansion and heart function. COS-7 cells transfected with a plasmid with an elastin gene fragment or a vector were seeded into a Gelfoam mesh and cultured. Mechanical stretch test (n = 5/group) showed that the elastin mesh was more elastic (P < 0.05) and tensile (P < 0.05) than the vector mesh. In an in vivo study in rats, 6 days after left anterior descending coronary artery ligation, COS-7 cells (Cell group, n = 7) or COS-7 cells with elastin gene (Elastin group, n = 9) or vector (Vector group, n = 9) were transplanted into the infarct; infarcted rats served as controls (n = 7). Over 8 wk the Cell group did not demonstrate effects on scar expansion and deterioration of heart function vs. controls. In contrast, infarct expansion was smaller and heart function was better maintained in the Elastin group vs. the Vector group (P < 0.05). At 8 wk after cell transplantation Langendorff data showed that the Elastin group had greater (P < 0.01) developed pressure and a smaller left ventricular volume than the Vector group. Western blot and histology showed accumulated elastin in the Elastin group infarct. Changing the extracellular matrix composition of a myocardial infarct by increasing elastin fragment content attenuated scar expansion, ventricular dilation, and onset of heart dysfunction.

myocardial infarction; ventricular modulation; gene therapy; cell transplantation


ELASTIN IS ONE OF THE MAJOR insoluble extracellular matrix components. Cross-linked elastin interacts with fibrillin to form elastic fibers. Because of its deformability and passive recoil without energy input, the elastic fiber provides properties of elasticity and resilience to tissues such as blood vessels, lungs, and skin (6).

The myocardium has few elastic fibers. Physiologically, elasticity of the myocardium is due to cardiomyocyte muscle bundles. After a myocardial infarction, necrosed myocardium is replaced by fibroblasts and predominantly type III collagen. No elastic fibers are present in the scar tissue. The infarcted regional elasticity depends on the ratio of fibrous to muscular tissue and the density of the collagen cross-links (2, 12). Because matured myocardial scar tissue is mainly composed of nonelastic type III collagen fibers and few cells, increased left ventricular (LV) chamber stiffness results in diastolic dysfunction (4, 14, 16). Because the infarct region is weak and the intraventricular pressure stresses the infarcted area with each contraction, the scar expands and the LV chamber dilates over time (9, 15). Stiffness and enlargement of the scar and LV decrease cardiac function (18). Our hypothesis is that alteration of scar composition by the introduction of elastin should increase the compliance and elasticity of the infarcted region and preserve scar size, ventricular chamber size, and cardiac function. Because the life span of the elastic fibers is in terms of years, cardiac function could also be stabilized for years.

In the present study we transfected a fragment of the elastin gene into a cell line that was implanted into a myocardial infarct scar before scar expansion occurred. Although the implanted COS-7 cells alone did not affect scar size and cardiac function, the presence of elastin fragment expressed by genetically modified COS-7 cells implanted in the scar limited scar expansion, ventricular dilation, and onset of heart dysfunction.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In Vitro Study

Preparation and transfection of rat tropoelastin gene. With total RNA isolated from rat aorta, cDNAs of a fragment of rat tropoelastin gene were synthesized by the RT-PCR technique with primers (forward primer: AAA AAA CTC GAG ATC CCA GGT GTT GGG, reverse primer: AAA AAA TCT AGA TCC AAG ATC ACC AGG). The cDNA was confirmed by sequence, tagged with NH2-terminal chicken cartilage link protein 60 (LP60) protein, and then ligated with a plasmid vector (pcDNA3.0, Invitrogen). The plasmids were amplified with Escherichia coli, and purified plasmids were used for the studies.

COS-7 cells (American Type Culture Collection) were cultured for 24 h in culture medium [Iscove's modified Dulbecco's medium (IMDM) including 10% fetal bovine serum] before transfection. The cells were washed with phosphate-buffered saline, and 10 ml of serum-free IMDM was added to the flask. The plasmid containing elastin gene (50 µg) or plasmid vector and 20 µl of Lipofectamine 2000 (Invitrogen Life Technologies) were suspended in 1 ml of serum-free IMDM. The COS-7 cells were incubated with this mixture for 6 h. The cells were then washed and cultured for 48 h before cell transplantation.

Assessment of recombinant elastin expression. To assess the expression of the recombinant elastin, 2 x 106 cells were collected, lysed, and centrifuged. The supernatants were used for the assays. The culture medium was also collected and centrifuged, and the supernatants were used for the assays. Each sample was denatured in SDS solution, and 30 µg of protein was electrophoresed in stacking and separating gels containing 4 and 10% polyacrylamide, respectively. The gels were blotted onto nitrocellulose membranes. After the membranes were blocked, the membranes were immersed with the primary antibody against NH2-terminal LP60 protein (a gift from Dr. B. B. Yang, Sunnybrook Hospital, Toronto, ON, Canada) at 4°C overnight. After being washed, the membrane was incubated with the secondary antibody (goat anti-mouse IgG antibody) at room temperature for 1 h, followed by another 1-h wash. The membranes were then exposed to ECL reagents (Amersham) and X-ray films, followed by film development.

Stretch test. The physical characteristics of the recombinant elastin in a gelatin mesh (Gelfoam, Pharmacia & Upjohn, Kalamazoo, MI) were measured by stretch testing with the Instron 8501 Dynamic Biomechanical Testing System.


CELL SEEDING. The gelatin Gelfoam mesh (30 x 30 x 2 mm) was incubated in culture medium for 2 days before cell seeding. The meshes were then attached to Bio-Stretch cell culture dishes, which were rectangular and allowed for fixation of the mesh by clipping to the inner aspect of the dish margin. The opposite free margin of each mesh was clipped to a cylindrical coated steel bar. COS-7 cells were transfected with the elastin gene (Elastin group) or the plasmid vector (Vector group) as described in Preparation and transfection of rat tropoelastin gene. The transfected cells in suspension were seeded onto a Gelfoam mesh (5 x 106 cells/mesh). After 2 days of incubation, the seeded meshes (n = 5) were subjected to cyclical mechanical stretch.


MECHANICAL STRETCH. Mechanical stretch was applied to the cell-seeded Gelfoam mesh with the Bio-Stretch apparatus (1). The Bio-Stretch culture dish is placed in front of a magnet, and the movement of the steel bar is controlled by dynamically changing the magnetic field on the controller. The Bio-Stretch apparatus was programmed to deliver a 70% stretch length at a frequency of 90 cycles/min for 2 days, followed by a uniaxial tension test as described previously (1).


ANALYSIS OF TENSILE STRENGTH. Uniaxial tension testing was performed with the Instron 8501 Dynamic Biomechanical Testing System (1). Gelfoam meshes were attached on opposite ends to the test apparatus. One arm of the test apparatus progressively stretched (0.5 mm/min) the mesh until failure (complete tear). The passive tensile strength of the patch was continuously recorded during the displacement. The data were plotted as the displacement in millimeters and the force in newtons. The tissue elasticity was determined as the area under the curve, the tissue resistance to stretch as the slope of the curve, and the maximum tensile strength as the peak force (1).

Histological study. After mechanical testing the Gelfoam meshes were rinsed three times in PBS and fixed in 10% phosphate-buffered formalin solution for 5 days. The meshes were embedded in paraffin and sectioned at a 10-µm thickness. The sections were stained with hematoxylin and eosin and trichrome staining as described by the manufacturers.

In Vivo Study

All experimental procedures were approved by the Animal Care Committee of the University Health Network and conformed to the guidelines in the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1985). The rats used in the experiment were male Lewis rats (Charles River, Canada).

Myocardial infarction. Under general anesthesia (20 mg/kg ketamine, 22 mg/kg pentobarbital, and inhalation of isoflurane 1–2%), rats were ventilated and the left anterior descending artery (LAD) was ligated via left thoracotomy. The rats received antibiotics (Duplocillin LA, 150,000 IU/kg; Intervet Canada) intramuscularly every 3 days for a week after surgery and buprenorphine (0.01–0.05 mg/kg) subcutaneously after the surgery and later as required. To minimize variation of infarct size and cardiac function, echocardiography was performed 5 days after LAD ligation, and the animals were selected according to the following criteria: infarct length >0.7 cm and <1.1 cm and percent fractional area shortening (%FAS) >20% and <40%.

Cell transplantation. Six days after LAD ligation, the heart was exposed via median sternotomy. To estimate the effects of COS-7 cells alone on cardiac function, 2 x 106 COS-7 cells (Cell group, n = 7) were injected into scar tissue with an insulin syringe and a 28-gauge needle. LAD ligation alone was performed as a control (Control group, n = 7). Cyclosporine (5 mg·kg–1·day–1) was injected subcutaneously into the rats in both groups daily during the study. Cardiac function was evaluated by echocardiography before and 8 wk after cell transplantation and by Langendorff study at 8 wk after cell transplantation as described in Measurement of cardiac function. After the functional study, the hearts were arrested with saline containing 20 meq/l potassium chloride and fixed with formalin at a pressure of 30 mmHg. The fixed hearts were cut into 3-mm-thick slices, and the scar size was measured by planimetry as described previously (17).

To estimate the in vivo function of the recombinant elastin, 30 rats were selected and randomly divided into two groups at 6 days after LAD ligation. COS-7 cells (2 x 106) transfected with the elastin gene (Elastin group) or the plasmid vector (Vector group) were transplanted into the infarcted area. Cyclosporine (5 mg·kg–1·day–1) was injected subcutaneously daily during the study. Two rats in each group were killed at 2 days and 2 and 5 wk after cell transplantation, and the scar was divided into two pieces. One half was fixed with 10% formalin for histology, and the other half was immediately frozen and stored at –80°C for assessment of elastin expression. The remaining nine rats in each group were used for functional assessment. Echocardiography was performed at 2 days and 2, 5, and 8 wk after cell transplantation, and the Langendorff study was performed at 8 wk. After the functional study, the scar was divided into two pieces for histology and assessment of the recombinant elastin. The frozen samples were homogenized, lysed, and centrifuged, and the supernatant was used for assessment of the gene expression as described in Assessment of recombinant elastin expression.

Measurement of cardiac function. Cardiac function was monitored with echocardiography (Sequoia Echocardiography System, ACUSON). The rats were anesthetized and maintained by 1.5–2.0% of inhaled isoflurane. The heart rate was kept higher than 300 beats/min. The short-axis views were recorded at the site where the maximal infarct area could be seen. The infarct length was determined as the maximum length of the akinetic wall at the end-diastolic phase. The area of the LV at the end-diastolic phase and the end-systolic phase was measured, and %FAS was calculated as [(LV end-diastolic area) – (LV end-systolic area)]/(LV end-diastolic area). The parameters were measured at 6 beats and averaged.

The cardiac function was also assessed 8 wk after cell transplantation with a Langendorff apparatus as we described previously (8). In brief, under general anesthesia, the heart was quickly excised and perfused in a Langendorff apparatus with filtered Krebs-Henseleit buffer equilibrated with 5% carbon dioxide and 95% oxygen. A latex balloon was inserted into the LV. After 20 min of stabilization, balloon volume was increased in 0.02-ml increments by addition of saline. LV systolic and end-diastolic pressures and maximum and minimum change of pressure with time (dP/dtmax, dP/dtmin) were recorded at each balloon volume. Developed pressure (DP) was calculated as the difference between the systolic and diastolic pressures.

Histological assessment. The fixed scar tissue were embedded in paraffin and cut into 10-µm-thick slices. The slices were stained with hematoxylin and eosin staining and elastica-van Gieson staining. To assess immunorejection, the tissues were also immunostained with antibody against CD4.

Data Analysis

All results are presented as means ± SE. Comparison in the stretch test was performed by Student's t-test. Comparisons of ventricular functional data over the 8 wk by echocardiography were performed by two-way repeated-measures ANOVA. The ventricular functional data from the Langendorff preparation were analyzed with SPSS system software. A value of P < 0.05 was considered statistically significant.


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In Vitro Studies

The transfection efficiency of the cultured COS-7 cells was >90%. Newly synthesized recombinant elastin molecules were observed in both the cell lysate and the culture medium in the Elastin group (Fig. 1, A and B). No elastin gene expression was detected in the Vector group.



View larger version (60K):
[in this window]
[in a new window]
 
Fig. 1. In vitro study: COS-7 cells were transfected with a plasmid containing an elastin fragment gene with a NH2-terminal LP60 tag (Elastin) or a plasmid vector (Control). The newly synthesized elastin fragments were detected with an antibody against the LP60 tag in medium cultured with elastin-transfected COS-7 cells (A) and lysate of elastin-transfected COS-7 cells (B) immediately before implantation into myocardial infarct scar tissue. No elastin molecule was in the Control group. In vivo study: elastin-transfected COS-7 cells (Elastin) and vector-transfected cells (Control) were implanted into the myocardial scar tissue. The recombinant elastin fragments were detected in the scar 2 days (C), 2 wk (D), and 5 wk (E) after cell implantation. The elastin level was decreased at 8 wk (F). No elastin fragments were detected in the Vector group (Control) over the 8-wk period.

 
The stretch test showed that the elasticity and the maximum tensile strength (force required to rupture the mesh) of the Gelfoam mesh of the Elastin group (n = 5) were greater (P < 0.05 and P < 0.05, respectively) than in the Vector group (n = 5) (Fig. 2). There was no significant difference in tissue resistance between the two groups (P = 0.135).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2. Physical characteristics of Gelfoam seeded and cultured with COS-7 cells transfected with a plasmid containing or without a recombinant elastin fragment gene [Elastin (n = 5) and Vector (n = 5) groups, respectively] were evaluated with a stretch test. The Elastin Gelfoam was more elastic and more tolerant to passive force (maximum tensile strength) than the Vector Gelfoam. There was no difference in the resistance of the two Gelfoams. *P < 0.05.

 
Histological staining showed COS-7 cells in the Gelfoam meshes (Fig. 3, A and B), and more collagen fibers were expressed in the Elastin group (Fig. 3D). This was not observed in the Vector control group (Fig. 3C).



View larger version (125K):
[in this window]
[in a new window]
 
Fig. 3. Hematoxylin and eosin (H&E; A and B) and trichrome (C and D) staining of vector-transfected (A and C) and elastin gene-transfected (B and D) COS-7 cells in Gelfoam (x200). More collagen fibers (arrows) were observed in the Elastin group.

 
In Vivo Studies

As measured by echocardiography, transplantation of COS-7 cells (Cell group, n = 7) into the infarct scar did not affect %FAS and infarct length (P = 0.85, 0.78) compared with the non-cell-transplanted control infarct scar (n = 7). No difference was detected in the Langendorff study between the two groups (DP: P = 0.95; dP/dtmax: P = 0.43). Planimetry data also showed no difference in scar size between the two groups (P = 0.69).

When the elastin gene- or vector-transfected COS-7 cells were implanted into infarcted regions, differences in cardiac function and ventricular morphology were observed by echocardiography between the Elastin (n = 9) and Vector (n = 9) groups. Before cell transplantation there were no statistical differences in infarct length (0.83 ± 0.11 cm vs. 0.82 ± 0.08 cm) and %FAS (31.9 ± 4.7% vs. 30.5 ± 4.4%) between the two groups. Over the 8-wk study, the infarct length in the Vector group doubled, which was greater (P < 0.05) than the 58% increase in the Elastin group (Fig. 4A). Cardiac function in the Vector group deteriorated (%FAS: 30.5 ± 4.4% to 12.9 ± 2.8%) more (P < 0.05) than in the Elastin group (%FAS: 31.9 ± 4.7% to 22.6 ± 4.5%) (Fig. 4B)



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4. Echocardiographic measurements of infarct length and % fractional shortening of hearts with infarct scars implanted with COS-7 cells transfected with a plasmid containing or without a recombinant elastin fragment gene [Elastin (n = 9) and Vector (n = 9) groups, respectively]. A: the Elastin group had less (P < 0.05) infarct lengthening than the Vector group. B: cardiac function as measured by % fractional shortening was better (P < 0.05) maintained in the Elastin group than the Vector group. Results are expressed as means ± SE.

 
Langendorff measurements at 8 wk (Fig. 5) showed that DP and dP/dtmax in the Elastin group (n = 9) were significantly greater (P < 0.01 and P < 0.01, respectively) than in the Vector group (n = 9) at each end-diastolic pressure from 0 to 25 mmHg. dP/dtmin of the Elastin group was smaller than that of the Vector group (P < 0.01; Fig. 5C). Not only was the ventricular chamber size of the Elastin group smaller (P < 0.01) than that of the Vector group, it was less compliant (Fig. 5D).



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5. Langendorff measurements of developed pressure (DP; A), maximum change in pressure with time (dP/dt) (B), and minimum dP/dt (C) vs. left ventricular (LV) end-diastolic pressure (LVEDP) and LVEDP vs. balloon volume (D) of hearts with infarct scars implanted with COS-7 cells transfected with a plasmid containing or without a recombinant elastin fragment gene [Elastin (n = 9) and Vector (n = 9) groups, respectively] at 8 wk after implantation. The Elastin group had better cardiac function and less LV chamber enlargement than the Vector group.

 
Histological studies showed that although the transplanted COS-7 cells could be observed at the implanted scar at 2 days after cell transplantation, no elastin fragments were seen in the Elastin and Vector groups (Fig. 6, A and B). At 2 and 5 wk after cell transplantation elastin fragments were evident throughout the scar area only in the Elastin group (Fig. 6, C–F). The fragment fibers, deposited around the transplanted cells (Fig. 7, A and B), had a wavy structure (Fig. 7C). Transplanted COS-7 cells were observed in the myocardial scar tissue in both the Elastin and Vector groups, but the cell numbers decreased with time, especially in the border zone (Fig. 8, B and C). At 2 and 5 wk after transplantation inflammatory cells, indicative of immunorejection, had spread throughout the scar, especially around the transplanted cells. Some T cells were presented in the border zone at each time point, but the number was small (Fig. 8, Ab–Db). At 8 wk the elastin fragment content was significantly decreased in the Elastin group (Fig. 6H) and COS-7 cells were almost absent in the scar (Fig. 8D). The elastin histological results were confirmed by Western blot analysis. The elastin fragments in the scar tissue of the Elastin group were easily detectable at 2 days and 2 wk (Fig. 1, C and D). By 5 wk, the amount of elastin fragments had moderately decreased (Fig. 1E). At week 8, the signals of the elastin fragments were weak (Fig. 1F). No elastin fragments were detected by histological examination or by Western blot analysis in the scars of the Vector group over the 8-wk study period.



View larger version (137K):
[in this window]
[in a new window]
 
Fig. 6. Representative images of infarct scars implanted with COS-7 cells transfected with a plasmid containing or without a recombinant elastin fragment gene (Elastin and Vector groups, respectively) at different time points after implantation (x40). Van Gieson staining stained the elastin fragments (arrow) (D, F, and H). In the Vector group, no elastin fragments were detected at 2 days (A), 2 wk (C), 5 wk (E), and even 8 wk (G) after cell transplantation. In the Elastin group, no elastin fragment fiber was detected at 2 days (B), but at 2 and 5 wk (D and F) substantial amounts of elastin fragments were evident in the scar. At 8 wk (H), the elastin fragment levels had decreased to some extent. TC, transplanted cells.

 


View larger version (113K):
[in this window]
[in a new window]
 
Fig. 7. Representative images of infarct scars implanted with COS-7 cells transfected with a plasmid containing a recombinant elastin fragment gene at 2 (A) and 5 (B) wk after cell transplantation (x200). The elastin fragments (white arrows) were laid down between the transplanted cells (black arrows). At a higher magnification (x400, C) the elastin fragments had a wavy appearance in the scar tissue.

 


View larger version (101K):
[in this window]
[in a new window]
 
Fig. 8. Hematoxylin and eosin staining (Aa–Da) and immunostaining against T cells in the border zone (Ab–Db) of hearts transplanted with COS-7 cells transfected with a plasmid containing a recombinant elastin fragment gene. The number of transplanted cells decreased over the 8-wk period. Inflammatory cells were seen in the border zone. However, only a few T cells were observed at the implanted area (A: 2 days; B: 2 wk; C: 5 wk; D: 8 wk). Arrows indicate positively stained T cells.

 

    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
After a myocardial infarction, the necrosed myocardium is replaced with fibrotic tissue that lacks elasticity. A mature ventricular scar tissue is seven times stiffer than a fibromuscular defect and a normal myocardium (9). The nonelastic scar tissue is acutely strained with each heart contraction. Because the scar lacks significant shock-absorbing properties, it tears, expands, and thins with time. As explained by Laplace's law, large infarct scars are more prone than small scars to tearing, expansion, and thinning.

Recently, cardiomyocytes, skeletal muscle cells, smooth muscle cells, and bone marrow cells have been implanted into infarcted myocardium and have improved cardiac function after infarction (1, 3, 17, 20). The mechanism of action of transplanted cells is unknown. Accumulated evidence has indicated that implanted cell contractility is not essential to improve global function because no evidence showed contractility of implanted cells and transplantation of nonbeating cells, such as skeletal muscle cells and smooth muscle cells, also prevented heart failure (3, 20). In addition, the survival rate of implanted cells is only 20–30% and continues to decline with time (10). Therefore, it is unlikely that the remodeling benefits of cell transplantation can be attributed to the number, type, or contractile properties of implanted cells alone. We hypothesized that the implanted cells increase the elastic properties of the infarct scar and make it more resistant to the stresses of ventricular systole.

To confirm that newly synthesized elastin fragments had elastic properties and added tensile strength we seeded elastin fragment gene-transfected COS-7 cells (fibroblasts) into a gelatin Gelfoam mesh. The cells grew throughout the mesh and expressed elastin fragments. In addition, the elastin-transfected cells also secreted collagen in the mesh. Both elastin and collagen were structurally organized in the direction of the stretching force on the mesh. The physical properties of the Gelfoam mesh showed that the elastin fragments and collagen increased the mesh's elasticity and the tensile strength required to break down the mesh compared with the properties of the Gelfoam mesh seeded with vector-transfected COS-7 cells. The elastin fragments and collagen did not affect the biomaterial's stiffness.

To alter matrix composition and change the properties of the infarcted tissue, we introduced a fragment of the elastin gene by cell transplantation into a recent myocardial infarct scar of an adult rat. The gene-transfected COS-7 cells expressed a 600-base pair fragment of elastin that accumulated in the extracellular matrix at the implant site. The elastin and likely collagen were expressed as early as 2 days after cell transplantation. The accumulated elastic fragments and collagen fibers were laid down in the infarcted zone for at least 5 wk. In contrast, few elastin fibers and no significant increase in collagen content were observed in the Vector group. Significant differences of the infarct size and heart function were observed. The scar and ventricular chamber sizes in the Elastin group were smaller, and cardiac function was better preserved than in the vector-transfected COS-7 cell-transplanted hearts. The decrease of LV compliance in the elastin-transfected hearts was consistent with the infarct having recoil and tensile properties that contributed to cardiac output. The beneficial effect seen in the Elastin group was also likely contributed to by overexpression of collagen and collagen fiber formation as seen in the in vitro studies. We speculate that expression of the elastin fragments stimulated the synthesis and secretion of collagen in vivo and that these molecules formed an organized extracellular matrix structure that inhibited the negative structural changes of ventricular remodeling. Although the elastic fragment content in the scar was almost absent by week 8, scar size was still smaller, LV dysfunction was less, and compliance was better than those of the Vector control group. The loss of the elastin fragments and possibly collagen in the elastin-transplanted hearts would be expected to lead to the development of ventricular dysfunction similar to that found in the vector control hearts.

There are a number of possible mechanisms by which elastin fragments and likely synthesized collagen in a myocardial scar tissue could delay the onset of ventricular dysfunction. A more elastic, stronger scar could function as a shock absorber to cushion the stress and the tearing effect of the acute increase in intraventricular pressure on the scar during systole. The recoil of the elastic fragments in the scar could provide passive energy to return the scar size and ventricular chamber volume to precontractile dimensions. The matrix modulation caused by newly synthesized elastin and collagen should inhibit scar expansion and ventricular dilation. Alteration of myocardial matrix by overexpression of elastin and collagen fiber could affect apoptosis and decrease cardiomyocyte loss through an extracellular matrix modulation mechanism after myocardial infarction. However, more research is needed to define the beneficial changes in the infarcted heart.

Elastin fibers consist of a tropoelastin as a core and a cross-link with microfibrillin that provides elasticity to tissue (7, 11, 13, 19). Although it would have been better to have expressed the full length of the elastin molecule in the myocardial scar tissue, the rat elastin cDNA, 2595 base pairs long, was thought to be too challenging for us to clone and express. Because a fragment of elastin has been reported to have some properties of the elastin molecule in term of extensibility and resilience (5), we elected to clone a 600-base pair segment of rat tropoelastin. The fragment was located at the site between 1201 and 1800 base pairs. To identify the elastin fragment synthesized, the 600-base pair fragment was tagged with LP60. The protein synthesized by the plasmid was a fusion protein of an elastin fragment and a 60-amino acid chicken protein.

We used COS-7 cells as a carrier of elastin gene in the current study for the following reasons. 1) Transplantation of COS-7 cells alone into infarcted myocardial scar tissue did not limit scar expansion and did not improve cardiac function. Therefore, the COS-7 cell line provided an opportunity to investigate the functional effectiveness of an overexpressed elastin fragment in an infarct. 2) Nonviral transfection efficiency of COS-7 cells is >90%, and the cells actively synthesized and secreted the elastin fragment, which cannot be achieved with primary cultures of rat cells. The disadvantage of using COS-7 cells, which originated from the African green monkey kidney, is immunorejection of the xenogeneic cells. Immunorejection would kill the COS-7 cells and decrease the rate of synthesis of the elastin fragments. The fusion protein would have also been recognized as foreign and would probably cause immunorejection. The decrease of elastin synthesis from loss of the transplanted transfected COS-7 cells and the accelerated fusion protein degradation from the immunorejection could explain why the amounts of elastin fragments were decreased at 5 and 8 wk after transplantation. Future research is planned to evaluate an in vivo untagged elastin fragment dose-cardiac function response curve after genetically modified autologous cells are transplanted into myocardial scar tissue. In vitro measurements of the infarct scar's elastic and strength properties will be performed. The loss of elastin fragments from immunorejection will be minimal. In addition, the effect of expressed elastin on changes in collagen content, organization, and structure in the implanted area as well as in the noninfarcted myocardium will be evaluated.

In summary, early elastin fragment expression and likely collagen synthesis in an infarct scar altered the myocardial modulation process, prevented scar expansion, and delayed the onset of heart dysfunction. The results suggest that alteration of the extracellular matrix and an increase in the elastin and collagen content in a myocardial infarct can benefit myocardial contractile function.


    GRANTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
R.-K. Li is a Career Investigator of the Heart and Stroke Foundation of Canada. The study was funded by the Canadian Institutes of Health Research (MOP62698 and Heart and Stroke Foundation of Ontario (T5206) (R.-K. Li).


    FOOTNOTES
 

Address for reprint requests and other correspondence: R.-K. Li, Toronto General Hospital, NU 1–115, 200 Elizabeth St., Toronto, Ontario M5G 2C4, Canada (E-mail: renkeli{at}uhnres.utoronto.ca)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Akhyari P, Fedak PWM, Weisel RD, Lee JYJ, Verma S, Mickle DAG, and Li RK. Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts. Circulation 106, Suppl I: I-137–I-142, 2002.
  2. Forrest L and Jackson DS. Intermolecular crosslinking of collagen in human and guinea pig scar tissue. Biochim Biophys Acta 229: 681–689, 1971.[Medline]
  3. Ghostine S, Carrion C, Souza LC, Richard P, Bruneval P, Vilquin JT, Pouzet B, Schwartz K, Menasche P, and Hagege AA. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 106: I-131–I-136, 2002.
  4. Gupta KB, Ratcliffe MB, Fallert MA, Edmunds LH Jr, and Bogen DK. Changes in passive mechanical stiffness of myocardial tissue with aneurysm formation. Circulation 89: 2315–2326, 1994.[Abstract/Free Full Text]
  5. Keeley FW, Bellingham CM, and Woodhouse KA. Elastin as a self-organizing biomaterial: use of recombinantly expressed human elastin polypeptides as a model for investigations of structure and self-assembly of elastin. Philos Trans R Soc Lond B Biol Sci 357: 185–189, 2002.[CrossRef][Medline]
  6. Kielty CM, Sherratt MJ, and Shuttleworth CA. Elastic fibres. J Cell Sci 115: 2817–2828, 2002.[Abstract/Free Full Text]
  7. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, and Keating MT. Elastin is an essential determinant of arterial morphogenesis. Nature 393: 276–280, 1998.[CrossRef][Medline]
  8. Li RK, Jia ZQ, Weisel RD, Mickle DAG, Zhang J, Mohabeer MK, Rao V, and Ivanov J. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 62: 654–661, 1996.[Abstract/Free Full Text]
  9. Markovitz LJ, Savage EB, Ratcliffe MB, Bavaria JE, Kreiner G, Iozzo RV, Hargrove WC 3rd, Bogen DK, and Edmunds LH Jr. Large animal model of left ventricular aneurysm. Ann Thorac Surg 48: 838–845, 1989.[Abstract]
  10. Muller-Ehmsen J, Whittaker P, Kloner RA, Dow JS, Sakoda T, Long TI, Laird PW, and Kedes L. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 34: 107–116, 2002.[CrossRef][ISI][Medline]
  11. Nakamura T, Lozano PR, Ikeda Y, Iwanaga Y, Hinek A, Minamisawa S, Cheng CF, Kobuke K, Dalton N, Takada Y, Tashiro K, Ross J Jr, Honjo T, and Chien KR. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 415: 171–175, 2002.[CrossRef][Medline]
  12. Parmley WW, Chuck L, Kivowitz C, Matloff JM, and Swan HJ. In vitro length-tension relations of human ventricular aneurysms: relation of stiffness to mechanical disadvantage. Am J Cardiol 32: 889–894, 1973.[ISI][Medline]
  13. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T, Biery NJ, Dietz HC, Sakai LY, and Ramirez F. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci USA 96: 3819–3823, 1999.[Abstract/Free Full Text]
  14. Pfeffer JM, Pfeffer MA, Fletcher PJ, and Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol Heart Circ Physiol 260: H1406–H1414, 1991.[Abstract/Free Full Text]
  15. Pfeffer MA and Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161–1172, 1990.[Abstract/Free Full Text]
  16. Raya TE, Gay RG, Lancaster L, Aguirre M, Moffett C, and Goldman S. Serial changes in left ventricular relaxation and chamber stiffness after large myocardial infarction in rats. Circulation 77: 1424–1431, 1988.[Abstract/Free Full Text]
  17. Tomita S, Li RK, Weisel RD, Mickle DAG, and Jia ZQ. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100: II-247–II-256, 1999.
  18. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, and Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44–51, 1987.[Abstract/Free Full Text]
  19. Yanagisawa H, Davis EC, Starcher BC, Ouchi T, Yanagisawa M, Richardson JA, and Olson EN. Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature 415: 168–171, 2002.[CrossRef][Medline]
  20. Yoo KY, Li RK, Weisel RD, Mickle DAG, Li GM, Kim EJ, Tomita S, and Yau TM. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg 70: 859–865, 2000.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
P. Farahmand, T. Y.Y. Lai, R. D. Weisel, S. Fazel, T. Yau, P. Menasche, and R.-K. Li
Skeletal Myoblasts Preserve Remote Matrix Architecture and Global Function When Implanted Early or Late After Coronary Ligation Into Infarcted or Remote Myocardium
Circulation, September 30, 2008; 118(14_suppl_1): S130 - S137.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Robinet, H. Millart, F. Oszust, W. Hornebeck, and G. Bellon
Binding of elastin peptides to S-Gal protects the heart against ischemia/reperfusion injury by triggering the RISK pathway
FASEB J, July 1, 2007; 21(9): 1968 - 1978.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Duca, C. Blanchevoye, B. Cantarelli, C. Ghoneim, S. Dedieu, F. Delacoux, W. Hornebeck, A. Hinek, L. Martiny, and L. Debelle
The Elastin Receptor Complex Transduces Signals through the Catalytic Activity of Its Neu-1 Subunit
J. Biol. Chem., April 27, 2007; 282(17): 12484 - 12491.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/6/H2819    most recent
00862.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mizuno, T.
Right arrow Articles by Li, R.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mizuno, T.
Right arrow Articles by Li, R.-K.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.